After abandoning its first initial public offering (IPO) filed in 2021, natural killer (NK) cell therapy specialist Artiva ...
Novo Nordisk's parent company Novo Holdings has led a $100 million third-round financing for Swiss biotech Asceneuron, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results